Scandinavian ChemoTech

Scandinavian ChemoTech's Animal Care has received an initial order valued to USD 37,000 from a veterinary clinic in Ottawa, Canada. This order is contingent upon a successful electrical safety test conducted by a third-party testing facility. Since the vetIQure™ device is based on the same platform as the CE-marked IQwave™, the testing process is expected to be successful and take approximately 3-6 weeks.

Capital City Specialty & Emergency Animal Hospital is part-owned by Dr. Julius M. Liptak, a highly respected figure in veterinary surgical oncology. Dr. Liptak's passion and commitment to this field were developed during his residency training in Australia and further honed as a Fellow in Surgical Oncology at the Animal Cancer Center at Colorado State University, which is renowned as one of the premier training programs for veterinary surgical oncologists globally.

"It feels promising that we have reached a level in North America where we believe we can begin our commercialization efforts in Canada. As sales increase, we will gradually expand our sales force in the North American market," says Mohan Frick, CEO of ChemoTech.

Canada, 77% of households own at least one type of pet. According to Statista, there were 28.05 million pets in Canada, up from 27.93 million in 2020. It is predicted that the number of pets will rise to over 28.5 million by 2025. The most popular pets to own are cats followed by dogs. 23% of Canadian households have a cat, while 20% have a dog. 13% of households in Canada have both cats and dogs.

(https://madeinca.ca/pet-ownership-statistics-canada/

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-05-2024 07:55 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.